本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、审议程序 公司于 2025 年 8 月 26 日召开的第四届董事会第十次会议、第四届监事会 第八次会议审议通过了《2025 年半年度利润分配预案》，本议案尚需提交公司股 东大会批准。 二、利润分配预案的基本情况 （一）本次利润分配预案的基本内容 1、分配基准：2025 年半年度 2、根据公司 2025 年半年度财务报告（未经审计），公司 2025 年半年度合并 会计报表归属于母公司股东的净利润为人民币 65,925,139.11 元，2025 年半年度 母公司实现净利润 113,971,209.90 元；截至 2025 年 6 月 30 日，公司合并报表累 计可供股东分配的利润为 684,121,241.04 元，母公司累计可供股东分配的利润为 695,149,110.91 元。 证券代码：002940 证券简称：昂利康 公告编号：2025-064 浙江昂利康制药股份有限公司 关于 2025 年半年度利润分配预案的公告 三、现金分红方案合理性说明 本次利润分配方案符合相关法律法规和《公司章程》以及《公司未来三 ...

Core Viewpoint - The company, Anglikang, has signed a licensing agreement with Aifei Biopharmaceutical and Qinhuli Biopharmaceutical, granting it exclusive rights to develop, manufacture, and commercialize the drug molecule IMD-1005 in China, including mainland China, Hong Kong, Macau, and Taiwan [1] Group 1 - The company will make an initial payment of 150 million RMB to Aifei and Qinhuli, with potential milestone payments to Qinhuli not exceeding 620 million RMB for research and sales [1] - The company is also obligated to pay a sales share of 12.8% to Qinhuli during the sales revenue sharing period [1] - IMD-1005 is an innovative tumor microenvironment-activated IgG1 subtype antibody targeting CD47, which is expected to provide new immunotherapy options for cancer patients [1]

Core Viewpoint - The announcement highlights a strategic collaboration between the company, Aifei Bio, and Qinhuli, focusing on the licensing of the IMD-1005 drug molecule, granting the company exclusive rights for research, production, and commercialization in specified regions [1] Group 1 - The company signed a licensing agreement with Aifei Bio and Qinhuli for the IMD-1005 drug molecule [1] - The company will pay a total of 150 million RMB as an initial payment to Aifei Bio and Qinhuli [1] - The company may pay up to 620 million RMB in milestone payments related to research and sales to Qinhuli [1] Group 2 - The company is required to pay a sales share of 12.8% to Qinhuli during the sales revenue sharing period [1]

Core Viewpoint - The company, Anglikang, plans to invest 389 million yuan in a new project to produce 8,000 tons of Amoxicillin and 2,000 tons of Ampicillin in Shengzhou, Zhejiang Province, enhancing its product layout in the anti-infection field and improving supply chain stability [1] Investment Details - The total planned investment for the project is 389 million yuan [1] - The project aims to establish self-sufficient raw material production capacity [1] Strategic Goals - The investment will strengthen the company's upstream raw material supply stability [1] - The project is expected to enhance industry chain collaboration efficiency [1] - It aims to improve cost control and market competitiveness [1] - The initiative is positioned to lay a solid foundation for sustainable development [1]

浙江昂利康制药股份有限公司 2025 年半年度报告全文 浙江昂利康制药股份有限公司 2025 年半年度报告 2025 年 8 月 1 所有董事均已出席了审议本次半年报的董事会会议。 本报告涉及未来计划等前瞻性陈述，不构成公司对投资者实质承诺，投 资者及相关人士均应当对此保持足够的风险认识，并且应当理解计划、预测 与承诺之间的差异。 行业监管及行业政策变化、生产成本持续上涨、集中带量采购、环保政 策、安全生产、人才缺乏及核心技术人员流失、新产品研发、规模扩张引致 的管理风险等风险，有关风险因素已在本报告"管理层讨论与分析"部分予 以描述。上述风险提示未包括本公司可能发生但未列示的其他风险，请投资 者谨慎投资！ 公司经本次董事会审议通过的利润分配预案为：以 196,108,486 股为基数， 向全体股东每 10 股派发现金红利 1.00 元（含税），送红股 0 股（含税），不以 公积金转增股本。 2 浙江昂利康制药股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 ...

Company Overview - Zhejiang Anglikang Pharmaceutical Co., Ltd. is located at 1000 North Shengzhou Avenue, Shengzhou City, Zhejiang Province, established on December 30, 2001, and listed on October 23, 2018. The company's main business involves the research, production, and sales of chemical raw materials and formulations [1][2]. Financial Performance - As of March 31, 2025, Anglikang reported a revenue of 346 million yuan, a year-on-year decrease of 15.31%, and a net profit attributable to shareholders of 15.91 million yuan, down 43.63% year-on-year [2]. - The company has cumulatively distributed 341 million yuan in dividends since its A-share listing, with 108 million yuan distributed over the past three years [3]. Stock Performance - On August 27, Anglikang's stock price fell by 2.04% to 51.80 yuan per share, with a trading volume of 303 million yuan and a turnover rate of 3.11%, resulting in a total market capitalization of 10.45 billion yuan [1]. - Year-to-date, Anglikang's stock price has increased by 296.69%, with a 4.75% rise over the last five trading days, a 0.38% decline over the last 20 days, and a 209.85% increase over the last 60 days [1]. Shareholder Information - As of March 31, 2025, Anglikang had 12,300 shareholders, an increase of 10.23% from the previous period, with an average of 15,104 circulating shares per shareholder, a decrease of 9.28% [2]. - Among the top ten circulating shareholders, Xinyi Medical Care A (011466) ranked as the eighth largest, holding 1.1006 million shares, a decrease of 288,300 shares from the previous period [3]. Industry Classification - Anglikang belongs to the pharmaceutical and biological industry, specifically in the chemical pharmaceutical and chemical formulation sectors. The company is associated with concepts such as ursodeoxycholic acid, hypertension treatment, Helicobacter pylori concepts, synthetic biology, and innovative drugs [2].

从资金流向来看，8月26日主力资金净流出5809.46万元，占流通市值的0.59%。不过近五个交易日整体 呈现净流入状态，累计净流入5533.16万元。 该公司属于化学制药板块，主营业务为医药产品的研发、生产和销售。作为浙江地区的医药企业，昂利 康在合成生物和创新药领域有所布局。 风险提示：股市有风险，投资需谨慎。 昂利康8月26日股价呈现震荡走势，最终收于52.88元，较前一交易日下跌4.93%。盘中最高触及58.93 元，最低下探52.69元，振幅达11.22%。当日成交量为19.1万手，成交金额10.55亿元。 ...

Market Overview - The chemical pharmaceutical sector experienced a decline of 1.33% on August 26, with Yuan Dong Biological leading the drop [1] - The Shanghai Composite Index closed at 3868.38, down 0.39%, while the Shenzhen Component Index closed at 12473.17, up 0.26% [1] Stock Performance - Notable gainers in the chemical pharmaceutical sector included: - Haixiang Pharmaceutical (002099) with a closing price of 6.41, up 6.13% [1] - ST Suwu (600200) with a closing price of 1.11, up 4.72% [1] - Maiwei Biological (688062) with a closing price of 42.50, up 4.14% [1] - Major decliners included: - Yuan Dong Biological (688513) with a closing price of 63.08, down 10.71% [2] - Guangsheng Tang (300436) with a closing price of 138.88, down 8.60% [2] - Shutaishen (300204) with a closing price of 56.70, down 7.05% [2] Capital Flow - The chemical pharmaceutical sector saw a net outflow of 30.51 billion yuan from institutional investors, while retail investors contributed a net inflow of 18.08 billion yuan [2] - The sector's capital flow indicates a mixed sentiment, with institutional investors withdrawing funds while retail investors increased their positions [2] Individual Stock Capital Flow - Haixiang Pharmaceutical (002099) had a net inflow of 78.77 million yuan from institutional investors, while retail investors saw a net outflow of 77.68 million yuan [3] - Other notable stocks with significant capital flows included: - Borui Pharmaceutical (688166) with a net inflow of 78.36 million yuan from institutional investors [3] - Yifang Biological (688382) with a net inflow of 28.31 million yuan from institutional investors but a net outflow of 89.39 million yuan from retail investors [3]

Group 1 - The innovative drug sector in the A-share market has experienced a decline, with several companies showing significant drops in stock prices [1] - Yuan Dong Biological fell over 8%, while Sunshine Nuohe dropped over 6%, and other companies like Haitai Biological and Guangshantang saw declines exceeding 5% [1] - The overall trend indicates a challenging environment for the innovative drug sector, as multiple companies are facing downward pressure on their stock performance [1] Group 2 - Specific stock performance data shows Yuan Dong Biological at -8.86% with a market capitalization of 11.4 billion, and Sunshine Nuohe at -6.99% with a market cap of 8.334 billion [2] - Other notable declines include Haitai Biological at -5.87% (7.32 billion), Guangshantang at -5.49% (22.9 billion), and Yifang Biological at -4.88% (23.2 billion) [2] - Year-to-date performance reveals that despite recent declines, some companies like Guangshantang and Aong Likang have shown substantial increases of 339.58% and 304.97% respectively [2]

Group 1 - The innovative drug sector in the A-share market has experienced a decline [1] - Yuan Dong Biological has dropped over 8% [1] - Sunshine Novo has decreased by more than 6% [1] Group 2 - Hai Te Biological and Guangsheng Tang have both fallen over 5% [1] - Yi Fang Biological, Li Fang Pharmaceutical, Kang Chen Pharmaceutical, Ang Li Kang, and Ou Lin Biological have all seen declines of over 4% [1]